Menarini is seeking approval of Factive for the treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis. The regulatory review time in Europe is approximately 12 months.
Steven Rauscher, president and CEO of Oscient, said: “Menarini’s pursuit of marketing approval for Factive in Europe is an important step in our commercialization plan for Factive in our licensed territories. Menarini is a strong, experienced partner, and we look forward to working together to build the Factive brand in Europe.”